{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:20:14Z","timestamp":1747196414379,"version":"3.40.5"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The response to the vaccine may vary among individuals. Hence, it is important to know how often individuals experience side effects after immunization against COVID-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>This study aimed to assess the incidence of side effects following COVID-19 vaccination across different vaccine recipients in Southern Pakistan and identify the potential factors associated with these side effects in the population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The survey was conducted across Pakistan through Google-forms Links from August to October 2021. The questionnaire included demographic information and COVID-19 vaccine information. Chi-square (<jats:italic>x<\/jats:italic><jats:sup>2<\/jats:sup>) was performed for comparative analysis to check the significance level with <jats:italic>P &lt;0<\/jats:italic>.<jats:italic>05<\/jats:italic>. The final analysis included 507 participants who had received COVID-19 vaccines.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of the total 507 COVID-19 vaccines recipients, 24.9% received CoronaVac, 36.5% received BBIBP-CorV, 14.2% received BNT162b2, 13.8% received AZD1222, and 10.7% received mRNA-1273. The most prominent side effects after the first dose were fever, weakness, lethargy, and pain at the site of injection. Moreover, the most commonly reported side effects after the second dose were pain at the injection site, headache, body ache, lethargy, fever, chills, flu-like symptoms, and diarrhea.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our results suggested that the side effects due to COVID-19 vaccination can vary between the first and second doses and type of COVID-19 vaccine. Our findings suggest continuing monitoring of vaccine safety and the importance of individualized risk-benefit assessment for COVID-19 immunization.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0285736","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:13:25Z","timestamp":1684865605000},"page":"e0285736","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of post-vaccine side effects among COVID-19 immunized community of Southern Pakistan"],"prefix":"10.1371","volume":"18","author":[{"given":"Ali","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-2802","authenticated-orcid":true,"given":"Syed Azhar","family":"Syed Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajiha","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-2315","authenticated-orcid":true,"given":"Sumaira","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"article-title":"Vaccines & Immunizations: Centers for Disease Control and Prevention","year":"2021","author":"Centers for Disease Control and Prevention","key":"pone.0285736.ref001"},{"issue":"1","key":"pone.0285736.ref002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","article-title":"Towards effective COVID\u201119 vaccines: Updates, perspectives and challenges","volume":"46","author":"D Calina","year":"2020","journal-title":"International journal of molecular medicine"},{"article-title":"Vaccine: Encyclopedia Britannica","year":"2020","author":"EK Brunson","key":"pone.0285736.ref003"},{"issue":"10234","key":"pone.0285736.ref004","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(20)30763-7","article-title":"Ensuring global access to COVID-19 vaccines","volume":"395","author":"G Yamey","year":"2020","journal-title":"The Lancet"},{"issue":"7","key":"pone.0285736.ref005","doi-asserted-by":"crossref","first-page":"e0270761","DOI":"10.1371\/journal.pone.0270761","article-title":"Qureshi PAAA. Knowledge, perception, and fear among the global population towards newly evoked variant Omicron (B.1.1.529).","volume":"17","author":"A Qureshi","year":"2022","journal-title":"PloS one"},{"issue":"9","key":"pone.0285736.ref006","doi-asserted-by":"crossref","first-page":"M563","DOI":"10.1093\/gerona\/57.9.M563","article-title":"Effect of a complete nutritional supplement on antibody response to influenza vaccine in elderly people","volume":"57","author":"W Wouters-Wesseling","year":"2002","journal-title":"The journals of gerontology Series A, Biological sciences and medical sciences"},{"issue":"6","key":"pone.0285736.ref007","first-page":"946","article-title":"Etiological diagnosis and pharmacotherapeutic management of parapneumonic pleurisy","volume":"64","author":"D C\u0103lina","year":"2016","journal-title":"Farmacia"},{"issue":"1","key":"pone.0285736.ref008","first-page":"17","article-title":"Zinc and respiratory tract infections: Perspectives for COVID\u201119","volume":"46","author":"AV Skalny","year":"2020","journal-title":"International journal of molecular medicine"},{"issue":"2","key":"pone.0285736.ref009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/003335490712200215","article-title":"Immunity for the people: the challenge of achieving high vaccine coverage in American history","volume":"122","author":"J. Colgrove","year":"2007","journal-title":"Public health reports"},{"key":"pone.0285736.ref010","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3389\/fmed.2021.783982","article-title":"Systematic review and meta-analysis of COVID-19 vaccination acceptance","volume":"8","author":"MN Norhayati","year":"2022","journal-title":"Frontiers in medicine"},{"issue":"2","key":"pone.0285736.ref011","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: where we stand and challenges ahead.","volume":"28","author":"G Forni","year":"2021","journal-title":"Cell Death & Differentiation"},{"issue":"7798","key":"pone.0285736.ref012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/d41586-020-00751-9","article-title":"Don\u2019t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees","volume":"579","author":"S. Jiang","year":"2020","journal-title":"Nature"},{"issue":"4","key":"pone.0285736.ref013","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"C-T Tseng","year":"2012","journal-title":"PloS one."},{"issue":"8","key":"pone.0285736.ref014","doi-asserted-by":"crossref","first-page":"e0270900","DOI":"10.1371\/journal.pone.0270900","article-title":"Survey data of public in Sindh Pakistan regarding willingness to accept COVID-19 vaccination","volume":"17","author":"N Kumar","year":"2022","journal-title":"PloS one."},{"issue":"6494","key":"pone.0285736.ref015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"BS Graham","year":"2020","journal-title":"Science"},{"issue":"568","key":"pone.0285736.ref016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe0948","article-title":"Prospects for a safe COVID-19 vaccine","volume":"12","author":"BF Haynes","year":"2020","journal-title":"Science translational medicine"},{"issue":"1","key":"pone.0285736.ref017","first-page":"1","article-title":"COVID-19 Vaccination Efficacy and Safety Literature Review","volume":"3","author":"M Halim","year":"2021","journal-title":"Journal of clinical medicine research"},{"year":"2021","author":"World Health Organization","key":"pone.0285736.ref018"},{"key":"pone.0285736.ref019","unstructured":"Raosoft. Sample size calculator 2021 [Available from: http:\/\/www.raosoft.com\/samplesize.html."},{"key":"pone.0285736.ref020","unstructured":"National Command Operation Center. G.o.P. COVID Vaccination. 2021 [cited 2021 September 27] 2021 [Available from: https:\/\/ncoc.gov.pk\/covid-vaccination-en.php."},{"key":"pone.0285736.ref021","first-page":"538","article-title":"COVID vaccines and safety: what the research says","author":"A. Remmel","year":"2021","journal-title":"Nature Publishing Group"},{"issue":"4","key":"pone.0285736.ref022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"JR Teijaro","year":"2021","journal-title":"Nature Reviews Immunology"},{"issue":"7","key":"pone.0285736.ref023","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"C Menni","year":"2021","journal-title":"The Lancet Infectious diseases"},{"issue":"7","key":"pone.0285736.ref024","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"C Menni","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"issue":"1","key":"pone.0285736.ref025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/vaccines10010109","article-title":"Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population","volume":"10","author":"MO Elgendy","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"pone.0285736.ref026","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12879-022-07974-3","article-title":"Side effects of Pfizer\/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community","volume":"23","author":"AD Abukhalil","year":"2023","journal-title":"BMC Infectious Diseases"},{"issue":"8","key":"pone.0285736.ref027","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/biology10080752","article-title":"Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers","volume":"10","author":"M Klugar","year":"2021","journal-title":"Biology"},{"issue":"7","key":"pone.0285736.ref028","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm10071428","article-title":"Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic.","volume":"10","author":"A Riad","year":"2021","journal-title":"Journal of clinical medicine"},{"issue":"12","key":"pone.0285736.ref029","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/jcm10122629","article-title":"Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey","volume":"10","author":"A Riad","year":"2021","journal-title":"Journal of clinical medicine"},{"key":"pone.0285736.ref030","article-title":"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial.","author":"Y-J Zhang","year":"2020","journal-title":"medrxiv"},{"issue":"10240","key":"pone.0285736.ref031","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"F-C Zhu","year":"2020","journal-title":"The Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:13:52Z","timestamp":1684865632000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285736"}},"subtitle":[],"editor":[{"given":"Sampson","family":"Twumasi-Ankrah","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0285736","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}